Efficacy of statin treatment based on cardiovascular outcomes in elderly patients: a standard meta-analysis and Bayesian network analysis.

Abstract

OBJECTIVE:

Statins have been shown to be beneficial for the prevention of cardiovascular events. In elderly individuals, the efficacy of statins remains controversial and the comparative effect of statins has not been assessed.

METHODS:

MEDLINE, Embase, and the Cochrane Central database were searched for randomized controlled trials that assessed statins in older patients.

RESULTS:

Seventeen trials were analyzed. When used for secondary prevention, statins were associated with reduced risk of cardiovascular events, all-cause mortality, cardiovascular mortality, revascularization, and stroke. When used for primary prevention, statins reduced the risk of myocardial infarction and revascularization, but did not significantly affect other outcomes. A modest difference between pharmaceutical statin products was found, and high-quality evidence indicated that intensive atorvastatin had the greatest benefits for secondary prevention.

CONCLUSIONS:

In secondary prevention, evidence strongly suggests that statins are associated with a reduction in the risk of all-cause mortality, cardiovascular events, cardiovascular mortality, and revascularization. However, differences in the effects of various statins do not appear to have significant effects on therapy in secondary prevention for the elderly.

• Authors: Chuannan Zhai, Kai Hou, Rui Li, YueCheng Hu, JingXia Zhang, YingYi Zhang, Le Wang, Rui Zhang, HongLiang Cong
• Journal: The Journal of international medical research (J Int Med Res) Vol. 48 Issue 6 Pg. 300060520926349 (Jun 2020) ISSN: 1473-2300 [Electronic] England
• PMID: 32529863 (Publication Type: Journal Article, Meta-Analysis)

Chemical References

• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Atorvastatin

Topics

• Age Factors
• Aged
• Atorvastatin (therapeutic use)
• Bayes Theorem
• Cardiovascular Diseases (drug therapy, epidemiology, prevention & control)
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
• Incidence
• Mortality
• Primary Prevention (methods)
• Randomized Controlled Trials as Topic
• Secondary Prevention (methods)
• Treatment Outcome